Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chapman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chapman, M. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

How does nicotinic acid modify the lipid profile?

M. John Chapman

Dyslipidemia and Atherosclerosis Research Unit U 551 INSERM Hôpital de la Pitié 83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France

Corresponding author. Tel: +33 1 42 17 78 78; fax: +33 1 42 17 78 78. E-mail address: chapman{at}chups.jussieu.fr

An atherogenic dyslipidaemic phenotype, characterized by low HDL-cholesterol levels, hypertriglyceridaemia and small, dense LDL, is commonly observed in patients with type 2 diabetes, the metabolic syndrome, or pre-existing cardiovascular disease and is inadequately addressed by current guidelines for the management of cardiovascular disease. Moreover, low HDL-cholesterol, in particular, is common among patients treated for dyslipidaemia and is little affected by statin treatment. Incomplete suppression of lipolysis by insulin in the fed state in insulin-resistant subjects leads to increased lipolysis in adipose tissue with elevated circulating free fatty acids (FFA). This metabolic abnormality leads directly to the development of the atherogenic dyslipidaemic phenotype. Nicotinic acid increases levels of HDL-cholesterol, probably largely through suppression of lipolysis in adipocytes secondary to activation of specific, G-protein-coupled nicotinic acid (HM74A) receptors. The reduction in FFA flux after nicotinic acid treatment also results in reduced levels of circulating triglycerides, mainly in the form of VLDL, and increased size and buoyancy of LDL. Treatment with nicotinic acid equally increases the size of HDL particles, which may promote increased reverse cholesterol transport from macrophages in the atherosclerotic plaque via the ABCG1 cholesterol transporter. The effects of nicotinic acid on the lipid profile are thus potentially anti-atherogenic and may address a major source of cardiovascular risk in insulin-resistant populations, such as those with the metabolic syndrome, type 2 diabetes and/or cardiovascular disease.

Key Words: HDL-cholesterol • Atherosclerosis • Dyslipidaemia • Nicotinic acid • Niacin • Lipolysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.